HR and breast cancer: The combination of inavolisib, a PI3Kα-selective inhibitor, with palbociclib and fulvestrant was recently approved by the FDA for the treatment of patients with HR+/HER2-, PIK3CA-mutated advanced, or metastatic BC [35].